Hørsholm, Denmark, January 31, 2020 – Oncology Venture A/S today announces that investor warrants, series TO2, will be traded on Nasdaq First North starting on February 4, 2020, under the short name OV TO 2 and ISIN code DK0061153657.
One (1) investor warrant received when participating in the rights issue in Oncology Venture at the end of 2019 gives the right to subscribe for one (1) new share in Oncology Venture A/S at an issue price of 6.00 SEK. The total number of warrants in series TO 2 is 50,341,080.
Investors in the Rights Issue will have the possibility to exercise their warrants in five two-week windows during the 24-months period during which the warrants may be exercised.
These periods are:
- April 1, 2020 – April 15, 2020
- September 1, 2020 – September 15, 2020
- February 1, 2021 – February 15, 2021
- May 1, 2021 – May 15, 2021
- September 1, 2021 – September 15, 2021
Instructions on how to exercise the warrants will be made available two weeks ahead of the first exercise period.
For further information, please contact:
Henrik Moltke, CFO
Telephone +45 53 63 96 37
About Oncology Venture A/S
Oncology Venture A/S (Nasdaq First North Growth Market Stockholm: OV.ST) develops drugs for personalized treatment of cancer guided by its proprietary drug response predictor technology, DRP®. The Company’s current priority program focus is for advancement of 2X-121, IXEMPRA®, and Dovitinib: 2X-121 – a PARP inhibitor in Phase 2 for ovarian cancer; IXEMPRA® (Ixabepilone) – an approved and marketed (U.S.) microtubule inhibitor being advanced for Phase 2 development (in EU) for treatment of breast cancer; Dovitinib – a post Phase 3 product, being prepared for a US NDA approval filing in renal cell carcinoma (RCC). In addition, the company holds the rights for additional four programs: LiPlaCis® – a liposomal formulation of cisplatin for the treatment of breast cancer; 2X-111 – a targeted, liposomal formulation of doxorubicin for the treatment of breast cancer; Irofulven – a DNA damaging agent for the treatment of breast cancer; and APO010 – an immuno-oncology product for the treatment of multiple myeloma.
About the Drug Response Predictor – DRP® Companion Diagnostic
Oncology Venture uses its drug specific DRP® to select those patients who, by the genetic signature of their cancer, are found to have a high likelihood of responding to the specific drug. The DRP® method builds on the comparison of sensitive vs. resistant human cancer cell lines, including genomic information from cell lines combined with clinical tumor biology and prior clinical trial outcomes. The DRP® platform can be used in all cancer types and is patented for more than 70 anti-cancer drugs in the U.S.
Follow us on social media:
This announcement includes forward-looking statements that involve risks, uncertainties and other factors, many of which are outside of OV’s control and which could cause actual results to differ materially from the results discussed in the forward-looking statements. Forward-looking statements include statements concerning OV’s plans, objectives, goals, future events, performance and/or other information that is not historical information. All such forward-looking statements are expressly qualified by these cautionary statements and any other cautionary statements which may accompany the forward-looking statements. OV undertakes no obligation to publicly update or revise forward-looking statements to reflect subsequent events or circumstances after the date made, except as required by law.
Svensk Kapitalmarknadsgranskning AB, Email: email@example.com. Tel: +46 11 32 30 732